Diagnostic tools: Various tests to diagnose and manage
hepatitis C including various biochemical marker, imaging, liver biopsy for
grading/staging liver disease and HCV RNA (viral load) tests.
·
Biochemical/Imaging
o 212. Independent evaluation of 4 blood scores of liver
fibrosis in chronic hepatitis C: FibroMeter, Fibrotest, Hepascore and APRI
o 219. A simple and economical score can often displace
other invasive or costly methods to evaluate liver fibrosis in chronic
hepatitis C virus infection
o 221. A Single Tube Multiplex Research Assay to Assess
the Risk of Cirrhosis in Subjects with Chronic Hepatitis C
o 223. Direct serological markers of liver fibrogenesis
improve the diagnostic accuracy of indirect markers for liver fibrosis in
chronic hepatitis C patients
o 224. Reproducibility of blood scores of liver fibrosis
o 226. The AST to Platelet Ratio Index Does Not
Accurately Predict Significant Fibrosis in HCV/HIV Coinfected Patients with Low
CD4 T Cell Counts
o 231. Optimization of the diagnosis of cirrhosis
comparing clinical, biochemical and radiological features with liver stiffness by
FibroScan
o 232. Transient elastography
in chronic hepatitis C - comparison between different noninvasive methods for
liver fibrosis assessment
o 234. A screening test for thrombosis risk factors as a
new biological marker of liver fibrosis in patients with chronic hepatitis C
virus (HCV) infection
o 235. Accurate Identification of Liver Fibrosis by a
Continuous 13C Methacetin Breath Test in
Patients with Chronic HCV Infection and Normal or Near-Normal Liver Enzymes
o 237. Increased Anti-ARFP Antibody Positivity
is Associated with End-Stage Liver Disease
o 238. Diagnostic accuracy of blood tests of liver
fibrosis for severe fibrosis and cirrhosis in patients with chronic viral
hepatitis
o 239. Meta-analysis of blood scores for liver fibrosis
in chronic hepatitis C
o 243. Diffusion-weighted MR imaging for the diagnosis of
liver fibrosis in patients with chronic hepatitis C (updated October 28,
2006)
o 249. European liver fibrosis (ELF) markers accurately
distinguish fibrosis severity in Chronic Hepatitis C (CHC); an external validation
study in a population-based cohort
o 250. FIBROSpect II and Image
Analysis in the Evaluation of Chronic Hepatitis C
o 341. Evaluation of fibrosis regression using
non-invasive methods in very long-term follow-up of HCV responder patients
o 354. Transient elastography (fibroscan©) in chronic hepatitis C. Will it modify the
assessment and the follow-up of treated patients?
o 373. The international autoimmune hepatitis group
scoring system in patients with Chronic Hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy: a
prospective validation study
o 391. Evaluation of fibrosis evolution using non-invasive
methods according to sustained virological response in HCV patients. A pilot
prospective controlled study
o 702. Assessment of the severity of cirrhosis according to different values
of FibroScan : a prospective study (updated October 29,
2006)
o 705. A preliminary evaluation of a novel biomarker of renal function,
Neutrophil Gelatinase-Associated Lipocalin
(NGAL), in patients with liver disease
o 707. Noninvasive diagnosis of the degree of hepatic fibrosis using serum
markers and ultrasonography in patients with chronic
hepatitis B
o 709. Liver stiffness measurement by transient elastography:
predictive factors of accuracy, success and reproducibility (updated October 29,
2006)
o 710. Combination of blood scores, Doppler ultrasonography,
and transient elastography for the diagnosis of liver
fibrosis (updated October 29, 2006)
o 720. Enhanced Quantitative Liver Spleen Scan (QLSS) Prediction of Liver
Disease Severity in Baseline HALT-C Patients with Moderate Fibrosis or
Cirrhosis
o 743. Liver stiffness measurement by transient elastrography
(Fibroscan): is training necessary?
o 749. Prospective assessment of liver stiffness for the non-invasive
diagnosis of portal hypertension (updated October 30, 2006)
o 1148. Prospective Comparison of Two Commercial
Non-invasive Fibrosis Serum Marker Panels (FibroSure
and FibroSpect II) Before and During Therapy with
albumin interferon alfa-2b in A Chronic HCV Genotype 1 Population (updated October 31,
2006)
·
Biopsy
o 165. Longitudinal analysis of fibrosis progression in
chronic hepatitis C using analysis of multiple biopsies and Generalized
Estimating Equations (GEE)
o 506. Prospective Audit of Liver Biopsy Practice: Is
Bigger Better? (updated October 31, 2006)
o 507. Patient Experience of Day Case Liver Biopsy:
Prospective Audit (updated October 29, 2006)
·
General
o 689. Validation of the Short Form of Liver Disease Quality of Life (LDQOL)
Instrument
o 692. A simple scoring system accurately predicts outcome in patients with
chronic liver disease admitted to a Liver Intensive Care Unit
o 700. Hand grip test is a valuable tool for screening of malnutrition in patients
with liver cirrhosis: prospective analysis in 138 patients (updated October 29,
2006)
·
Viral load
o 213. Hepatitis virus C RNA quantification by automated Cobas AmpliPrep-Cobas TaqMan 48 (CAP-CTM) real-time PCR assay: an evaluation of
performance
o 225. Evaluation of an automated, highly sensitive, real
time PCR based assay (COBAS ampliprep / COBAS taqman) for quantification of HCV RNA
o 233. Ultracentrifugation of serum samples allows
detection of HCV-RNA in patients with occult HCV infection
o 236. Accurate quantification and sensitive detection of
hepatitis C virus RNA using a single automated assay in the clinical setting.